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Abstract 
Phytoestrogens are a family of diverse polyphenolic compounds derived from 
nature plant that structurally or functionally mimic circulating estrogen in the 
mammalian reproductive system. They induce estrogenic and anti-estrogenic 
effects in the brain-pituitary-gonad axis (a principal endocrine system involving 
in reproductive regulation) and peripheral reproductive organs. The dichotomy 
of phytoestrogen-mediated actions elucidates that they play the biological 
activities via complex mechanisms and belong to various chemical classes. In 
comparison with their unobvious physiological functions in normal reproductive 
tissues, there are increasing investigations showing that phytoestrogen induces 
significant inhibitory effects on the growth of breast and ovarian cancers through 
different signaling pathways. This review summarized the results of the previous 
studies regarding principal signaling transductions for mediating the growth of 
the ovarian and breast cancers. Phytoestrogen potentially modulates the 
signaling molecules via: (1) blocking the nuclear and membrane estrogen 
receptors (ER), (2) interfering with the growth factor receptor, (3) inhibiting the 
G protein-coupled receptor in ER-deficient cells, (4) activating apoptosis and 
nullifying anti-apoptotic signals. 
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Introduction 
Phytoestrogen refers a group of polyphenolic molecules originating from exogenous nature 
dietary plant source, including several family members such as flavones (Kaempferol and 
quercitin) (Fig.  1A), isoflavones (genistein, daidzein, formononetin and equol) (Fig.  1B), 
lignans (enterolactone, enterodiol and nordihydroguaiaretic  acid), coumestanes 
(coumestrol) (Fig.  1C), mycotoxins (zearalenol) and stilbens (resveratrol) (Fig.  1D) [1]. 
Several plants are dietary consumption of human and animals, such as, soys and beans, 
containing high levels of various phytoestrogens which exhibit hormone-like functions in 
the mammalian reproductive system [2]. The mechanism of the phytoestrogen bioactivity 
might be the possible binding to estrogen receptors (ERs) because of its structural 
similarity with estradiol (E2, 17β-estradiol) (Fig.  1E). The binding affinity to ERs is 
determined by a planar ring system, two ring structures divided by two carbon atoms, and 
spacing between hydrophobic and hydrogen bond interaction [3]. Although most of 
phytoestrogens have the weaker ER-binding affinities than natural estrogens, they play 
diverse significant estrogenic or anti-estrogenic roles on the regulation of reproduction-
related organs [4, 5]. The classic biological effect of E2 is mediated through two distinct 
intracellular receptors, ERα and ERβ. ERα is a major subtype in the tissues of breast, 
uterus, cervix, vagina and other reproductive organs. ERβpimarily distributes in the ovary, 
prostate, testis, spleen, lung, hypothalamus and thymus [6]. Phytoestrogen exhibits a low 
affinity for binding to ERα suggesting their weak estrogenic activities (10
−2–10
−3-fold) in 
comparison with E2, whereas they also exert partial anti-estrogenic effect because of 
relatively preferentially binding to ERβ [1,  7]. The dichotomy of classic ER modulating 
action induced by phytoestrogen probably provides an explanation on conflicting evidence 
about the risks and benefits of dietary phytoestrogens in research presenting a 
contradictory picture in the mammalian reproductive system.  
Phytoestrogen is demonstrated to exert various biological activities that are not mediated 
by activating nuclear ER [8,  9]. In human aortic smooth muscle cells, phytoestrogen 
showed an inhibitory effect on mitogen-induced proliferation, migration and extracellular 
matrix synthesis via down-regulating the signaling pathway of mitogen-activated protein 
kinases (MAPK) [10]. Quercetin, a flavone, exerted a dual effect on regulating the activities 
of the protein kinases in Ehrlich ascites tumor cells through increasing the cyclic AMP 
(cAMP)-dependent and decreasing the cAMP-independent protein kinase activities [11]. 
The ER-dependent and ER-independent effect of phytoestrogen indicate multiple 
mechanisms directing potential physiological and/or pharmacological actions in 
reproductive system and relevant diseases [12]. Herein, we will focus on considering the 
multiple effects of these phytoestrogen molecules on circulating estrogen-regulated 
endocrine systems which are involved in controlling mammalian reproduction. 
Furthermore, we will summarize the biological activities of phytoestrogen on various 
signaling pathways in the mammalian breast and ovarian cancer cells.   Phytoestrogen Actions on Reproduction and Cancers  3 
Sci Pharm. 2011; 79: 1–20 
A 
O
O
OH
OH
O H
OH
R
kaempferol  R = H
quercetin  R = OH  
 
O O H
O
R
2 R
1
genistein R
1 = OH, R
2 = OH
daidzein R
1 = H, R
2 = OH
formononetin R
1 = H, R
2 = OCH3  
O O H
OH
equol  
B 
O
O H
OH
O
enterolactone  
O H
OH
OH
OH
enterodiol  
C 
nordihydroguaiaretic acid
O H
OH O H
OH
 
O
O
O O H
OH
coumestrol  
D 
O H
OH
O
O
OH
zearalanol  
O H
OH
OH
resveratrol  
E 
estradiol
OH
O H
H
HH
 
 
Fig. 1.   The structures of various phytoestrogens.  4  E Zhao and Q. Mu:   
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Discussion 
Phytoestrogen targets in reproductive system 
Phytoestrogen actions in the brain-pituitary-gonad axis 
The brain-pituitary-gonad axis is the principal endocrine system to regulate mammalian 
reproduction. In this axis, reproductive regulation by the brain involves a complex 
interaction of different endocrine factors controlling pituitary gonadotropin hormone 
release, such as gonadotropin releasing hormone (GnRH), dopamine and γ-aminobutyric 
acid. In mammals, gonadotropin hormones are classified as follicle stimulating hormone 
(FSH) and luteinizing hormone (LH). Both FSH and LH are released into the general 
circulation to stimulate sex steroid production, including those of E2 and testosterone (T), 
and to control ovulation in females or sperm generation in males. On the other hand, E2 
not merely modulates the function of reproductive organs, e.g. breast, ovary and testis, but 
also has positive and negative feedback roles on gonadotropin or its upstream hormone 
synthesis and secretion, through direct interaction with ER [13]. Therefore, similar to the 
structure of E2 [3], phytoestrogen plays a role in mimicking or antagonizing the E2 
function. This point is worth considering in this system.  
In the brain, GnRH is known and named for its function as the final common hypothalamic 
signal peptide to regulate reproduction. It is reported that GnRH is modulated by 
phytoestrogen. The flavanone 8-prenylnaringenin, identified as a potent phytoestrogen and 
an estrogenic compound, exhibited an E2-mimic negative feedback to inhibit the activity of 
the hypothalamic GnRH pulse generator and thereby serum LH levels in rat [14]. 
Coumestrol, another kind of phytoestrogen, exerted a direct inhibitory effect on GnRH 
gene expression in the GnRH neuron, and then elicited an inhibitory regulation on the 
reproductive system via binding to ERβ [15]. However, another investigation demonstrated 
that coumestrol inhibited GnRH effects on LH release by antagonizing the neuroendocrine 
action of estrogen thru ERα, suggesting that the estrogenic activity of phytoestrogen is 
mediated via different mechanisms in the brain [16].  
Considering phytoestrogen modulating gonaodotropin generation and secretion in the 
pituitary, the previous investigations exhibited some contradictory patterns. Whereas both 
the GnRH-inhibited effect of coumestrol and selective endocrine activity of genistein (an 
isoflavone) led to reducing LH release at the level of rat pituitary [17,  18], high-dose 
administration of dietary equol (another isoflavone metabolite) markedly enhanced serum 
LH level in the ovariectomized rat [19], and intracerebroventricular of ganister increased 
the percentage of LHβ-subunit gene expressing cells in the anoestrous ewe pituitary via 
activation of cellular ERα [20]. FSH is another kind of gonadotropin released from the 
pituitary. Genistein had no effect either on FSH cellular immunoreactivity or on the FSHβ 
gene expression possibly due to no ERα existence on FSH-gonadotrophs in ewe [20]. 
Dichotomal phenomenon of phytoestrogen on gonadotropin secretion has been also 
detected in a clinical study of postmenopausal women: mean LH release decreased after 
discontinuing dietary isoflavone intake, but one of these women was observed to have a 
higher LH secretion after treatment [21]. However, recent evidence that a high-dose and 
long-term treatment of dietary puerarian mirica (an herb containing phytoestrogen) might 
produce a clear reduction in the monkey urinary FSH levels, suggested the potential 
regulatory effect of phytoestrogen on FSH release [22]. The results obtained from clinical 
and experimental studied on the regulation of gonadotropin indicates the complex   Phytoestrogen Actions on Reproduction and Cancers  5 
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regulatory mechanism of phytoestrogen activities in the pituitary, and further studies are 
required to explore the signaling pathways in this modulation after phytoestrogen 
activation.  
Under the pituitary regulation, ovary is the female gonad organ that secretes steroid 
hormone and yields oocytes. Several lines of studies on steroidogenesis indicated the 
effects of phytoestrogen effects might be mediated indirectly via gonadotropin regulation or 
directly in the ovary. Previous results demonstrated that the treatments of dietary 
isoflavones will lead to a decrease, an increase or a lack of variation in serum 
progesterone (P4) and E2 levels. This fact suggested several inconsistent patterns of 
phytoestrogen regulatory abilities in ovarian granulosa cells [23]. Several investigations 
reported that the direct effect of phytoestrogen was related to modulation of steroidogenic 
enzymes in the steroid production process. Hydroxysteroid dehydrogenase/isomerase 
(3β-HSD) is a key enzyme to catalyze P4 production. Isoflavones inhibited the 3β-HSD 
enzyme activity via the post-cAMP pathway to reduce P4 generation in porcine ovary [24]. 
In the mammalian E2 synthesis, aromatase is an essential enzyme to aromatize T 
(released from theca cells) for producing E2 in ovarian granulose cells. It was noted that 
flavones and isoflavones dose-dependently inhibited of the generation of aromatase in 
human granulose-luteal cells [25,  26]. In addition, phytoestrogen was shown to play a 
critical role to control oocyte generation. Genistein exposure was able to inhibit oocyte 
nest breakdown and attenuate oocyte cell death during mouse oocyte development [27], 
and to decrease P4 and E2 concentration in mouse ovarian differentiation [28].  
The male testis contains the reproductive part and the endocrine part that play roles in 
sperm-forming and sex hormone (T) production, respectively. The previous research on 
phytoestrogen showed these compounds had various actions on steroidogenesis. In adult 
male rat, exposure to high-dose coumestrol has been demonstrated to reduce T levels, 
possibly mediated by ERβ [29]. In rat testicular Leyding cells, isoflavone decreased the 
cellular production of steroid hormone but increased serum levels of T under a high-dose 
and long-time treatment [30]. In comparison with the phytoestrogen effect on the oocyte 
generation, the administration of dietary phytoestrogen at a high level in male rats blocked 
spermatogenesis and induced germ cell apoptosis, possibly due to disruption of estrogenic 
regulation in testis [31]. Another line of evidence indicated simultaneous exposure to 
phytoestrogen and other endocrine disrupting compounds led to deterioration of male rat 
testis [32].  
Phytoestrogen actions in peripheral reproductive organs (prostate and breast) 
Prostate is a complex tubuloalveolar exocrine gland in the male mammalian reproductive 
system. There are few investigations concerning the effect of phytoestrogen on normal 
prostate. A histological study of calf prostate tissues did not show that phytoestrogen diet 
increased basal cell proliferation but elongated the basal cells in most animals [33]. 
Another study indicated that only a long-term exposure of dietary genistein induced a 
visible histological change in rat male prostate [34]. These two investigations indicated that 
phytoestrogen could not induce any significant modification in the normal mammalian 
prostate. However, phytoestrogen intake might offer protective effects against prostate 
cancer in clinical study [35]. The experimental studies on the mechanisms of its inhibitory 
activities against prostate cancer revealed that:  6  E Zhao and Q. Mu:   
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o  genistein showed an ability to avoid prostate cells from oxidative stress-
related DNA damage that accumulated progressively with age and led to prostate 
cancer [36];  
o  enterolactone, a major metabolite of plant-based lignans, induced loss of 
mitochondrial membrane potential, release of cytochrome C and production of 
caspase-3 in human prostate carcinoma, suggesting that a mitochondrial-mediated, 
caspase-dependent apoptosis pathway was activated to inhibit tumor cell 
proliferation [37];  
o  phytoestrogen led to an obvious increment of the ERβ generation, and ERβ 
is an essential factor to suppress the protstate tumor growth [38, 39].  
Breast glands are the important female peripheral organs for producing and secreting milk. 
Regarding phytoestrogen effects on this organ, the dietary genistein exposure could alter 
mammary development in neonatal mice [40]. Phytoestrogen has been reported to play a 
critical role in the protection against breast tumors, and the mechanisms of their activities 
in mammary cancer cells have been widely investigated, which we will consider minutely in 
the next chapter.  
Mechanisms of phytoestrogen effects on various reproductive cancers 
Recent studies in clinic indicated that dietary soy protein affected the growth of various 
reproductive cancers, such as breast and ovarian cancers [41–43]. Regarding the 
mechanisms of phytoestrogen effects on these cancers, the chemical structure of 
phytoestrogen resembles that of E2 suggesting that ER-activated genomic and/or non-
genomic signaling pathways might mediate principal function of phytoestrogen [3]. 
Moreover, other micro-environmental regulatory molecules regulated by phytoestrogen are 
also considered in these reproductive cancers.  
Phytoestrogen protection against breast cancer 
Breast cancer is a kind of common malignancies with the high mortality rate in Western 
population. However, the people in the Asian societies have much lower incidences of this 
cancer than the individuals from the Western societies. Several investigations have been 
performed to explain this phenomenon, for instance, the Japanese women had markedly 
high concentrations of circulating and excreting phytoestrogen, indicating that the low 
mortality in breast cancer might be due to high soy intake [44, 45]. Moreover, a case-
control study conducted among Asian-American women in Los Angeles County showed 
that soy intake reduced breast cancer risk, confirming the inverse association between 
dietary phytoestrogen and breast cancer [46]. Although phytoestrogen potentially exhibited 
an obvious protective effect in the breast cancer therapy in clinical studies, further basic 
biological investigations are necessary for obtaining theoretical support in the further 
experimental research. Herein, the mechanism of phytoestrogen action on integrating 
signaling pathways in breast cancer will be discussed for providing a molecular basis of 
future pharmacological studies of these compounds.  
The signaling pathways mediating the apoptosis, invasion, metastasis and proliferation of 
breast cancer cells have been simplified and described in Fig. 2, which potentially mediate 
the phytoestrogen effects on breast cancer. They are composed of nuclear ER (genomic   Phytoestrogen Actions on Reproduction and Cancers  7 
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ER)-initiated, membrane ER (non-genomic ER)-mediated, growth factor (GF)-transduction, 
G protein receptor (GPR)-directed, and apoptotic signaling pathways. The activated 
nuclear ERα and/or ERβ could induce the modification of gene expression in breast 
cancer. Although encoded by unique genes, ERα and ERβ have certain functional 
domains with a highly similar affinity to ligand- and DNA-binding sites, suggesting that 
these two receptors might play redundant roles. The mammary cell has a predominant 
distribution of ERα [6, 47]. In the classic pathway to activate transcriptomes, the activated 
ERs dimerizes and forms a complex for binding to a specific DNA sequence, the estrogen 
response element (ERE). In non-classic pathway, E2-ER complex interacts with several 
transcription factors such as AP1, SP1 and NFkB to modulate gene expression without 
ERE [48]. Another genomic pathway is mediate by a ligand-independent manner, showing 
that GF activates intracellular kinase pathway to phosphorylate ER at ERE-containing 
promoters [6]. Apart form nuclear genomic action, the membrane ER has been demon-
strated as a G protein-coupled receptor. The activated membrane ER induces the 
discretion of the G-protein α subunit to trigger the activation of Src kinases and PI3 kinase 
(PI3-K), respectively followed by downstream protein kinase C (PKC) and kinase cascade 
to extra-cellular regulated protein kinase (Erk), which are involved in proliferation and 
survival of breast cancer cells [47]. The PI3-K activation also triggers the recruitment of 
AKT, a serine-threnine kinase to control cell survival via activating downstream anti-
apoptotic signals (e.g. Bcl-2) and transcription factors (e.g. NFkB and CREB) [49, 50]. In 
addition, growth factor receptors (GFR), including insulin-like growth factor receptor (IGFR) 
and epidermal growth factor receptor (EGFR), are the other E2-membrane signaling 
pathways within breast cancer cells. IGFR mediates the signal pathway through tethering 
ERα to plasma membrane, activating EGFR, and initiating PI3-K and Erk signaling [51]. In 
the ER-negative breast cancer cell, E2 directly interacted with GPR30 to induce the 
activation of downstream Scr-coupled Erk and cAMP/PKA signaling networks via Gβg-
subunit protein [49]. The apoptotic signaling pathway is inactivated in most cancer cells, 
including a group of proteases such as caspase-8 and caspase-3 that cross-talk with EGF 
survival signaling network [50].  
The intracellular mechanisms of phytoestrogen protection against cellular proliferation of 
breast cancers might be via: (1) binding to nuclear ER and inhibiting genomic ER-
mediated gene expression, (2) interaction with membrane ER, blocking protein kinases 
and suppressing transcription factors, (3) inhibiting GFR activation and its downstream 
signaling networks, (4) activating caspases to initiate cellular apoptosis, (5) reducing the 
G-protein mediated signaling pathway in the ER-negative mammary cancer cell [red ham-
mers and blue arrows in Fig. 2]. The nuclear ER interaction is the most completely studied 
mechanism of phytoestrogen effect. The phytoestrogen-rich pueraria mirifica showed a 
strong competitive binding ability to ERα and/or possibly synthesized suppressor of ERα in 
the therapy of rat mammary tumor [52, Fig. 2-(1)]. Phytoestrogen is recently demonstrated 
to modulate ERα through the activation of ligand-independent pathway. Ginsenoside, a 
phytoestrogenic ingredient extracted from ginseng root, preferentially activated ERα via 
the phosphorylation of a transcription factor (AF-1) without the ligand-receptor interaction 
[53, Fig. 2-(2)]. However, isoflavone was demonstrated to selectively activate ERβ rather 
than ERα in the breast cancer cell line MCF-7, indicating a potential ERβ-relevant 
mechanism underlying protective effect of dietary phytoestrogen against mammary tumor 
[54, Fig. 2-(3)]. Moreover, genistein (an isoflavone) might induce a self-limiting mechanism 
of E2-stimulated ERβ gene expression in breast cancer cells [55, Fig. 2-(4)].  8  E Zhao and Q. Mu:   
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Fig. 2.   A dynamic model of phytoestrogen actions on modulating signaling pathways in 
the breast cancer cell. The arrows and hammers respectively present 
stimulation and inhibition. Abbreviations: E2, estradiol; PE, phytoestrogen; ER, 
estrogen receptor, mER; membrane estrogen receptor; ERE, estrogen 
response element; TF, transcription factor; P, phosphorylation; EGF, epidermal 
growth factor; IGF, insulin-like growth factor; GFR, growth factor receptor; SOS, 
son of sevenless; Grb, growth factor-bound protein; Ras, related RAS viral 
oncogene homolog; PI3-K, phosphatidylinositol 3-OH kinase; cAMP, cyclic 
adenosine 3',5'-monophosphate; CREB, cAMP response element binding 
protein; PKC, protein kinase C; Raf, v-raf-1 murine leukemian viral oncogene; 
Mek, mitogen/extracellular signal protein kinase; NFkB, nuclear factor-kappaB; 
PKA, protein kinase A; casp8, caspase-8; casp3, caspase-3. 
Although individual phytoestrogen interacted with various types of ER, most of 
phytoestrogen effects were ERα-dependent due to the predominant expression of this 
subtype in breast cells [6]. Furthermore, 8-prenylnaringenin was proven to activate 
membrane ERα and to interfere with an ER associated PI3-K pathway, resulting in the 
apoptosis and proliferation of MCF-7 breast cells [56, Fig. 2-(5)]. In the same cell line, 
resveratrol was also demonstrated to inactivate non-genomic ERα-mediated PI3-K/PKC 
signaling network because of lacking of a specific chemical structure part in this chemical. 
Meanwhile, resveratrol interfered with the Src-activated MAPK (including Mek and Erk) 
pathway, to reduce the generation of transcription factors [57, Fig. 2-(6)]. In ER-deficient   Phytoestrogen Actions on Reproduction and Cancers  9 
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mammary tumor cells, isoflavone selectively inhibited nuclear NFkB transduction of 
specific target gene through a new mechanism via depressing upstream Erk and Mek 
activities [58, Fig. 2-(7)]. Several other investigations have demonstrated the phyto-
estrogenic modulation of the PI3-K downstream signaling pathway. Genistein offspring not 
only elevated the quantity of ER binding sites, but also markedly repressed PKC activity in 
carcinogen-induced mammary tumorigenesis of female rats, [59, Fig. 2-(8)]. Regarding 
their regulatory effect on another downstream signaling, AKT, phytoestrogen stimulated 
the protein expression of the tumor suppressor PTEN that led to inhibiting the function of 
the AKT kinase in the growth of MCF-7 breast cancer cells [60, Fig. 2-(9)]. Bcl-2 is an anti-
apoptotic protein controlled by AKT kinase; genistein showed an inhibitory effect on the 
Bcl-2 phosphorylation in human breast cells [61, Fig. 2-(10)]. Licochalcone-A, a flavone-
like molecule, exerted an anti-tumor cytotoxic effect on MCF-7 cells in a manner of 
repressing the anti-apoptotic Bcl-2 and modifying the bcl-2/bax ratio to induce apoptosis 
[62, Fig. 2-(11)]. Regarding CREB (a signaling factor in the AKT pathway), isoflavone was 
capable of attenuating the interaction between the kinase and its promoters to decrease 
the cyclooxygenase-2 expression. The cyclooxgenase-2 is an important factor to mediate 
the breast carcinogenesis [63, Fig. 2-(12)].  
Besides modifying ER signaling networks, phytoestrogen, including genistein, exhibited a 
stimulatory action on the EGFR expression but did not trigger the activation of downstream 
signaling target (Mek and Erk) in the mammary gland, indicating a potential ER-
independent mechanism underlying their protection against breast cancer [64, Fig. 2-(13)]. 
In the ER-negative breast cancer cells, two major kinds of phytoestrogens, genistein and 
quercetin, modulated the activation of growth factors via the G protein-coupled receptor 
homologue GPR30. The competitive binding of phytoestrogens and natural E2 to GRP30 
were speculated as a new implication for understanding phytoestrogenic protection against 
breast cancer progression [65, Fig. 2-(14)]. Based on the finding of caspase-3 deficiency in 
MCF-7 cells, genistein exerted a significantly strong anti-tumor effect with the 
reconstitution of caspase-3, suggesting that a caspase-dependent pathway initiated by 
phytoestrogens to induce the apoptosis of breast cancer cells [66, Fig. 2-(15)]. Taken 
together, phytoestrogen plays an important role in modulating mechanisms of ER-
dependent and ER-independent signaling pathways, and would be recognized as a useful 
therapy for breast cancers in future clinical studies.  
Phytoestrogen effects on ovarian cancer 
Ovarian cancer is the most lethal disease affecting woman healthy, which is the sixth most 
common cancer and the fifth leading cause of cancer-related death in Western societies 
[67]. In comparison with the research in breast cancers, phytoestrogens were less 
considered and investigated in the therapy of ovarian cancers in human and other 
mammalian models. Until 1997, the first study on phytoestrogenic protection against the 
ovarian cancer was demonstrated that genistein exerted a synergetic action with quercetin 
to decrease proliferation of human ovarian carcinoma OVCAR-5 cells in vitro [68]. The 
following investigation detected the inhibitory actions of the isoflavone family against the 
ovarian cancer, including genistein and daidzein. These two isoflavones independently 
down-regulated the growth of two ovarian cancer cell lines, Caov-3 and NIH: OVCAR-3, in 
vitro [69]. Furthermore, an in vivo research concerning the 7,12-dimethyl-
benz[a]anthracene (DMBA)-induced rat ovarian carcinogenesis confirmed the anti-tumor 
activity of genistein in vitro [70]. In addition, a recent clinical report described that a woman 10  E Zhao and Q. Mu:   
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with platinum-refractory ovarian cancer entered into a phase of prolonged disease 
stabilization after a long-term intake of a soy beverage which contained rich of isoflavones, 
providing a strong support that phytoestrogens exerted a potential inhibitory effect on the 
human ovarian cancer [71]. These facts from the in vitro, in vivo and clinical research 
indicate that phytoestrogen might play a potential role to suppress the invasion, metastasis 
and growth of ovarian cancers.  
The molecular aspects of phytoestrogen effects on the growth and survival of ovarian 
cancer cells mainly include nuclear ER-regulated gene expression, GnRH receptor 
(GnRHR)-, FSH and/or LH receptors (FSHR/LHR)- and GFR-mediated signal transduction, 
and apoptotic signaling pathway, which are described in Fig. 3. ERβ but not ERα exhibits a 
primary expression in the ovary; and its function might be mostly modulated by nuclear 
ER-mediated signaling, including classical ligand-dependent, ligand-independent and 
ERE-independent manner [6]. Under the regulation of gonadotropin hormone secreted 
from the pituitary, ovarian cancers show the high expression of FSHR and LHR on the 
cellular membrane. The interaction between gonadotropin and FSH/LHR is considered to 
induce the proliferation of some ovarian cells, via the activation of the G-protein α subunit 
that rapidly increases the intracellular cAMP concentration. The cyclic AMP subsequently 
activates the downstream PKA. However, it is still unclear whether the action of FSH/LHR 
is also mediated by the ERK and/or PI3-K/AKT signaling pathways in ovarian cancer cells 
[67; 72]. Moreover, the activation of PI3-K and the phosphorylation of consequent AKT are 
the key signaling events for IGF interaction with GFR, providing a potential link with 
FSH/LHR-mediated signaling transduction in ovarian granulose cells. Moreover, GFR 
activation is also capable of initiating the Erk signaling cascade [72]. GnRH and its 
receptor are distributed in most of human ovarian epithelial tumors, showing anti-
proliferative activity via the activation of G protein and its following MAPK signal cascades 
(such as JNK). Furthermore, GnRH-activated receptor (GnRHR) induces the activation of 
p38 kinase and AP-1, and decreases the Erk function to inhibit proliferation of ovarian 
cancer cells [67]. The inhibition of the Fas/Fas ligand (FasL) apoptotic system maybe 
determines the growth of ovarian tumor. Regarding FasL-associated signaling 
transduction, FasL might interact with Fas receptor on the cell membrane to form a Fas-
DD complex. This complex activates caspase-8 protease, which recruits caspase-3 to an 
active form for the further induction of apoptosis [73].  
With regard to phytoestrogenic functions on modulating intracellular signals to affect the 
ovarian cancer growth [red hammers and blue arrows in Fig. 3], the previous research on 
the isoflavones showed that genistein and daidzein were capable of altering cytokine 
(interleukin-6) synthesis and attenuating ovarian cancer cell proliferation through activating 
the nuclear ER-dependent pathway [69, Fig. 3-(1)]. In EGFR-coupled signaling 
transduction of human ovarian tumor, genistein reduced the generation of Raf and its 
downstream signal molecules in vivo and in vitro [57, Fig. 3-(2)]. Furthermore, pre-
treatment of a soy bean trypsin inhibitor suppressed the transforming growth factor-
mediated activation of the Erk kinase; Erk is a major factors to mediate ovarian cancer cell 
invasion [74, Figure 3-(3)]. In addition, genistein decreased the level of phosphorylated  
   Phytoestrogen Actions on Reproduction and Cancers  11 
Sci Pharm. 2011; 79: 1–20 
 
 
Fig. 3.   A dynamic model of phytoestrogen actions on modulating signaling pathways in 
the ovarian cancer cell. Stimulation and inhibition are respectively indicated as 
arrows and hammers. Abbreviations: E2, estradiol; PE, phytoestrogen; ER, 
estrogen receptor; ERE, estrogen response element; TF, transcription factor; P, 
phosphorylation; GnRH, gonadotropin releasing hormone; GnRHR, GnRH 
receptor; FSH, follicle stimulating hormone; LH, luteinizing hormone; FSH/LHR, 
FSH and/or LH receptor; EGF, epidermal growth factor; IGF, insulin-like growth 
factor; GFR, growth factor receptor; PI3-K, phosphatidylinositol 3-OH kinase; 
cAMP, cyclic adenosine 3',5'-monophosphate; CREB, cAMP response element 
binding protein; Raf, v-raf-1 murine leukemian viral oncogene; Mek, 
mitogen/extracellular signal protein kinase; PKA, protein kinase A; FasL, Fas 
ligand; casp8, caspase-8; casp3, caspase-3; JNK, c-jun N-terminal kinase; AP1, 
activator protein-1; Ca
2+, calcium ion; Ca
2+
i, intracellular Ca
2+. 
AKT kinase, leading to apoptosis of ovarian cancer cells [75, Fig. 3-(4)]. Concerning other 
regulations of cellular apoptosis, genistein induced the gene expression of Fas (an 
apoptotic ligand), and suppressed bcl-2 transcription (an anti-apoptotic signal) in ovarian 
tumor-implanted nude mice [76, Fig. 3-(5)]. Moreover, caspase-3 function was activated by 
various doses of genistein treatments, suggesting another mechanism of anti-tumor effects 
for phytoestrogen to induce apoptotic pathway in the ovarian tumor growth [77, Fig. 3-(6)]. 
It is evident that several isoflavones inhibited aromatase, the enzyme that aromatize T to 12  E Zhao and Q. Mu:   
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E2, in human ovarian granulose cells. Genistein, biochanin A and daidzein exhibited the 
inhibitory activities on the aromatase production in vitro, indicating that the phytoestrogen-
induced aromatase suppression contributes to reducing the intracellular E2 production and 
subsequently inhibiting hormone-dependent ovarian cancer growth in an indirect manner 
[25, 26, Fig. 3-(7, 8)].  
Although phytoestrogen might modify several signal transductions to affect the ovarian 
tumor cell proliferation, there is remarkably less work in ovarian cancer than the 
widespread studies of phytoestrogens in breast cancer. How these compounds influence 
other major receptors (e.g. gonadotropin receptor and GnRHR) mediated signal cascades 
in the ovarian cancer cell is a key question to be clarified in the future investigations. 
Herein, in this paragraph, we will consider some potential regulatory effects of 
phytoestrogen, which are indicated as grey hatch hammers or arrows in Fig. 3; these 
activities have been demonstrated in other relevant vertebrate cells. With regard to 
GnRHR-activated signaling, the expressions and activities of c-Jun and AP1 transcription 
factors were abolished under the administration of the phytoestrogen α-zearalanol in 
human umbilical vein endothelial cells [78, Fig. 3-(a)]. Some certain phytoestrogens might 
modulate the FSH/LHR-mediated signaling pathways. Niculescu and her/his colleagues 
demonstrated that dietary isoflavones could induce the translation of various genes in 
human lymphocytes, including those encoding cAMP-activated and G protein-coupled 
signaling molecules [79, Fig. 3-(b)]. Moreover, the other finding confirmed that a 
nongenomic action of genistein contributed to activation of cAMP/PKA signaling system in 
intact bovine aortic endothelial cells and human umbilical vein endothelial cells [80, Fig. 3-
(c)]. Furthermore, genistein attenuated the calcium ion (Ca
2+) entry into fura-2-loaded 
human platelets, implying another role of phytoestrogens on the regulation of the cellular 
cAMP signaling system [81, Fig. 3-(d)]. On the transcriptional level inside the teleost cell 
nuclear, phytoestrogen was demonstrated to alter the gene expressions of Cyp 19 (gene 
encoding aromatase), cAMP responsive elements, ERE and half-EREs. It hinted a new 
cue to investigate potential phytoestrogen modulation on gene translation and transcription 
in mammalian cells, especially the ovarian cancer cell [82, Fig. 3-(e)]. 
Conclusion 
Most current investigations showed the dichotomal phenomenon and/or unobvious pattern 
of phytoestrogen influence on the reproductive system. Thus, it is speculated that 
phytoestrogen might not exhibit any significant toxicity or side-effect on the healthy 
reproductive organs, which needs to be clarified in the future. Furthermore, there has been 
a great development in understanding the mechanisms of the phytoestrogenic effects. 
These mechanisms mediated via diverse signaling pathways concerning proliferation of 
reproductive cancers are inside or outside cellular nuclear, ER-dependent or ER-
independent, and apoptotic or anti-apoptotic. Based on these previous evidences of 
phytoestrogen regulatory effects considered in this review, it is intriguing to deduce that 
phytoestrogens may have several remarkably pharmacological functions in the therapies 
of various hormone-dependent reproductive tumors in clinic. Consequently, the long-term 
research of phytoestrogens in the reproductive system will focus on determining the 
precise mechanisms of these phytoestrogen-associated compounds in the common 
malignant diseases (such as ovarian, prostate and uterus cancers), establishing the 
pharmacological and pharmacokinetic profiles for the individual phytoestrogen and/or its   Phytoestrogen Actions on Reproduction and Cancers  13 
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efficient extractions, and strengthening clinical studies on population or patients with or 
without dietary soy consumption. 
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